The 36 references in paper S. Avdeev N., С. Авдеев Н. (2014) “Перспективы терапии легочной артериальной гипертензии ингаляционным илопростом // Future development of therapy with inhaled iloprost in pulmonary arterial hypertension” / spz:neicon:pulmonology:y:2012:i:1:p:95-102

1
GaliéN., Hoeper M., Humbert M. et al.Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Heart J.
(check this in PDF content)
2
09; 30: 2493–2537. 2.Galie N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2009; 34: 1219–1263.
(check this in PDF content)
3
Galie N., Palazzini M., Manes A.Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed. Eur. Respir. J. 2010; 36: 986–990.
(check this in PDF content)
4
McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477–1482.
(check this in PDF content)
5
Sitbon O., Humbert M., Nunes H. et al.Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 2002; 40: 780–788. Рис. 6. Влияние терапии ингаляционным илопростом на гемодинамические параметры больных с легочным фиброзом [35]
(check this in PDF content)
6
Gomberg-Maitland M., Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur. Respir. J. 2008; 31: 891–901.
(check this in PDF content)
7
Hara S., Morishita R., Tone Y. et al.Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 1995; 216:
(check this in PDF content)
8
2–867. 8.Boxer L.A., Allen J.M., Schmidt M. et al. Inhibition of polymorphonuclear leukocyte adherence by prostacyclin. J. Lab. Clin. Med. 1980; 95: 672–678.
(check this in PDF content)
9
Tuder R.M., Cool C.D., Geraci M.W. et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 1999; 159: 1925–1932.
(check this in PDF content)
10
Christman B.W., McPherson C.D., Newman J.H. et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 1992; 327: 70–75.
(check this in PDF content)
11
Olschewski H., Walmrath D., Schermuly R. et al. Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension. Ann. Intern. Med. 1996; 124: 820–824.
(check this in PDF content)
12
Krause W., Krais T.Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur. J. Clin. Pharmacol. 1986; 30: 61–68.
(check this in PDF content)
13
Sablotzki A., Hentschel T., Gruenig E. et al. Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance. Eur. J. Cardiothorac. Surg. 2002; 22: 746–752.
(check this in PDF content)
14
Steudel W., Hurford W.E., Zapol W.M. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology 1999; 91: 1090–1121.
(check this in PDF content)
15
Gessler T., Schmehl T., Hoeper M.M. et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur. Respir. J. 2001; 17: 14–19.
(check this in PDF content)
16
Hoeper M.M., Schwarze M., Ehlerding S. et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N. Engl. J. Med. 2000; 343: 1866–1870.
(check this in PDF content)
17
Ventavis (iloprost). South San Francisco, Calif: Actelion Pharmaceuticals US Inc.; 2006.
(check this in PDF content)
18
Schermuly R.T., Schulz A., Ghofrani A. et al.Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. J. Pharmacol. Exp. Ther. 2002; 303: 741–745.
(check this in PDF content)
19
Olschewski H., Simonneau G., Galie N. et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 2002; 347: 322–329.
(check this in PDF content)
20
Dyke R.E., Nikander K. Delivery of iloprost inhalation solution with the halolite, prodose, and I-neb adaptive aerosol delivery systems: an in vitro study. Respir. Care 2007; 52: 184–190.
(check this in PDF content)
21
Krug S., Sablotzki A., Hammerschmidt S. et al.Inhaled iloprost for the control of pulmonary hypertension. Vascular Health and Risk Management 2009; 5: 465–474.
(check this in PDF content)
22
Walmrath D., Olschewski H., Grimminger F., Seeger W. NO and alternative inhalational therapy approaches in pulmonary hypertension. Internist (Berl) 1997; 38: 453–460.
(check this in PDF content)
23
Ewert R., Opitz C., Wensel R. et al.Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension. Z. Kardiol. 2000; 89: 987–999.
(check this in PDF content)
24
Olschewski H., Ghofrani H.A., Schmehl T. et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann. Intern. Med. 2000; 132: 435–443.
(check this in PDF content)
25
Olschewski H., Ghofrani H.A., Walmrath D. et al. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intens. Care Med. 1998; 24: 631–634.
(check this in PDF content)
26
McLaughlin V.V., Oudiz R.J., Frost A. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2006; 174: 1257–1263.
(check this in PDF content)
27
Hoeper M.M., Leuchte H., Halank M. et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2006; 28: 691–694.
(check this in PDF content)
28
Opitz C.F., Wensel R., Winkler J. et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur. Heart J. 2005; 26: 1895–1902.
(check this in PDF content)
29
D'Alonzo G.E., Barst R.J., Ayres S.M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 1991; 115: 343–349.
(check this in PDF content)
30
Bayer Schering Pharma AG. Open-label, uncontrolled, long-term surveillance study of iloprost aerosol inhalation therapy in the treatment of patients with primary or secondary pulmonary hypertension. Date last updated: May 2007.
(check this in PDF content)
31
Olschewski H., Hoeper M.M., Behr J. et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir. Med. 2010; 104: 731–740.
(check this in PDF content)
32
Frost A.E.,the STEP investigators. STEP-open label extension: long-term benefits of inhaled iloprost (ILO) addition to bosentan for treatment of pulmonary arterial hypertension (PAH). Am. J. Respir. Crit. Care Med. 2007; 175 (Suppl.): A1001.
(check this in PDF content)
33
Dernaika T.A., Beavin M., Kinasewitz G.T. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 2010; 79: 377–382.
(check this in PDF content)
34
Hegewald M.J., Elliott C.G. Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension. Chest 2009; 135: 536–537.
(check this in PDF content)
35
Olschewski H., Ghofrani H.A., Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. 1999; 160: 600–607.
(check this in PDF content)
36
Baughman R.P., Judson M.A., Lower E.E. et al.Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis. Vasc. Diffuse Lung Dis. 2009; 26: 110–120. Информация об авторе Авдеев Сергей Николаевич– д. м. н., проф., руководитель клиническо-
(check this in PDF content)